Steve Anderson, PhD
Chief Science Officer, Covance; Senior Vice President, LabCorp Drug Development
Steve Anderson, PhD
Chief Science Officer, Covance; Senior Vice President, LabCorp Drug Development
Dr Anderson is a senior vice president at Laboratory Corporation of America (LabCorp), and the Chief Scientific Officer for the Covance Drug Development business of LabCorp. He has been with the LabCorp organization for 26 years and has held a variety of positions including director of operations for ViroMed Laboratories, director of operations for Monogram Biosciences, director of operations for the Center for Molecular Biology and Pathology, director of operations for Integrated Oncology and Genetics, national director of Research and Development, and global head of LabCorp Clinical Trials. Dr Anderson is a member of a variety of professional societies including the American Association for Cancer Research, the American Society of Clinical Oncology and the Association for Molecular Pathology.
Dr Anderson’s research interests are in the development and applications for molecular diagnostics, including several examples of companion diagnostics and pharmacogenomics assays. He has authored more than 175 articles and abstracts published in such journals as Genetics, Proceedings of the National Academy of Sciences, Clinical Chemistry, the Journal of Infectious Disease, Human Pathology, American Journal of Obstetrics and Gynecology, Oncogene, the Journal of the National Cancer Institute, Clinical Cancer Research, Breast Cancer Research, BMC Cancer, the Journal of Molecular Diagnostics, Archives of Pathology and Laboratory Investigation and Expert Reviews in Molecular Diagnostics.
He has a PhD in genetics from Iowa State University, and was an American Cancer Society postdoctoral fellow at the Waksman Institute of Rutgers University.
Marilyn M. Bui, MD, PhD
Scientific Director, Analytic Microscopy Core; Section Head, Bone & Soft Tissue Pathology, Moffitt Cancer Center; Professor & Program Director, Cytopathology, University of South Florida Morsani College of Medicine
Marilyn M. Bui, MD, PhD
Scientific Director, Analytic Microscopy Core; Section Head, Bone & Soft Tissue Pathology, Moffitt Cancer Center; Professor & Program Director, Cytopathology, University of South Florida Morsani College of Medicine
Marilyn M. Bui, MD, PhD is a Senior Member in the Department of Pathology at Moffitt Cancer Center in Tampa, FL. She serves as the Scientific Director of the Analytic Microscopy Core and the Section Head of Bone & Soft Tissue Pathology. She is also a Professor and the Fellowship Program Director of Cytopathology at the University of South Florida Morsani College of Medicine. Her mission is to deliver the best possible patient care by combining her expertise in bone and soft tissue pathology, cytopathology, biomarker testing, and digital pathology/AI. She continuously discovers new knowledge through her research. Being an inventor, she has received patents in digital pathology and cancer diagnostics. She is the study pathologist for multiple research grants. She has published over 185 peer-reviewed articles, 24 book chapters and 3 books. Dr. Bui is an award-winning educator and mentor. Dr. Bui believes that service in professional societies is an important mechanism to help influence policies and standards to improve the quality of patient care in a broader sense. She serves on committees organizing national meetings on pathology education. She has frequently lectured both nationally and internationally, including keynote presentation. She is instrumental in developing the Digital Pathology Association’s Digital Anatomic Pathology Academy, a cloud-based whole slide image educational resource. Dr. Bui is the pathologist member of the National Comprehensive Cancer Network Soft Tissue Sarcoma Panel. She is the editorial board member of multiple journals. She is the President of the Chinese American Pathologists Association. She was the President of the Digital Pathology Association (2019) and the President of Medical Staff of Moffitt (2018-2020). She currently chairs and has chaired multiple committees of the College of American Pathologists (CAP). Dr. Bui is the recipient of several national awards including the 2019 CAP Distinguished Patient Care Award.
Thomas J. Fuchs, DrSc
Founder and Chief Scientist, Paige
Thomas J. Fuchs, DrSc
Founder and Chief Scientist, Paige
Dr. Thomas J. Fuchs is the Founder and Chief Scientist at Paige. He is a pioneer in the groundbreaking field of computational pathology, using artificial intelligence to analyze images of tissue samples to identify disease, recommend treatment and predict outcome and was named one of the Top 100 AI Leaders in Drug Discovery and Advanced Healthcare in 2019. He is also the Dean of Artificial Intelligence and Human Health and Co-Director of the Hasso Plattner Institute for Digital Health at the Icahn School of Medicine at Mount Sinai.
Previously, he was Associate Professor for Machine Learning at Weill-Cornell University, Director of the Warren Alpert Center for Digital and Computational Pathology at Memorial Sloan Kettering Cancer Center and Research Technologist at NASA’s Jet Propulsion Laboratory. Dr. Fuchs holds a Doctor of Sciences from ETH Zurich in Machine Learning and a MS in Technical Mathematics from Graz Technical University in Austria.
Alexander Haragan, MBBS, PhD
Pathology, NHS; Clinical Research Fellow, Pathology, Liverpool Clinical Laboratories, LLC
Alexander Haragan, MBBS, PhD
Pathology, NHS; Clinical Research Fellow, Pathology, Liverpool Clinical Laboratories, LLC
Dr Alexander Haragan is a MRC clinical research fellow and pathologist based in Liverpool with a clinical and research interest in thoracic and molecular pathology.
Graduating from the University of Aberdeen with his Medical Degree and first class honours in Biomedical Sciences, Dr Haragan also holds a distinction grade Masters in Pharmacogenomics and a PhD in Immuno-oncology and Clinical Pharmacology.
His main research interests are focused on immuno-oncology in NSCLC and predicting response to therapy and anticipating toxicities, as well as the integration of digital pathology and machine learning into the contemporary pathology laboratory.
Dr Haragan’s research has been funded with awards from prestigious funding bodies including the MRC and RCUK/UKRI Innovation Fellowship as well as being co-lead for the thoracic component of a £10.1 million investment from UKRI to expand digital pathology and AI programmes within the North of the UK as part of the Northern Imaging Pathology Co-operative.
Dr Haragan also sits as part of the UKNEQAS scientific advisory board and is on their expert panel for PD-L1 expression analysis and strongly believes in his working closely with industrial colleagues and public bodies as the key to successful future development of modern pathology.
Carlee Hemphill, MS
Lead Scientist, LabCorp Drug Development
Carlee Hemphill, MS
Lead Scientist, LabCorp Drug Development
Carlee is a Lead Scientist I at the Covance CDx laboratory in RTP, NC with a background in histology, anatomical pathology and bioinformatics. Her current role is the development of IHC or multiplex immuno florescence assays, or computational pathology algorithms, for clients interested in a complementary or companion diagnostic testing assay for their immuo-oncology pharmaceutical drug development pipeline.
Mike Montalto, PhD
Chief Scientific Officer, PathAI
Mike Montalto, PhD
Chief Scientific Officer, PathAI
Mike Montalto of PathAI has experience developing digital pathology diagnostic products and driving cutting-edge translational research in a large biopharmaceutical setting. Mike joined PathAI in November 2019 to use AI-powered pathology to support the development of new therapies and diagnostics for patients.
Prior to joining PathAI, Mike led the majority of clinical biomarker central laboratories in Translational Medicine at Bristol-Myers Squibb including translational and digital pathology, immunohistochemistry, clinical genomics, clinical flow cytometry, pre-clinical and clinical non-invasive imaging, biorepository and clinical biomarker sample operations in support of all therapeutic areas for global clinical trials, precision medicine, and companion diagnostics development. Prior to BMS, Montalto was a co-founder and executive of Omnyx, LLC, a joint venture of GE Healthcare and the University of Pittsburgh Medical Center that commercialized diagnostic pathology imaging and software products. Prior to this, Montalto was the Molecular Imaging and Diagnostics Advanced Technology Leader at General Electric, where he was a lead inventor of MultiOmyx™, a proprietary pathology-based multiplexing technology for biomarker discovery.
Throughout his career, Mike had a passion for advancing imaging technologies toward unmet scientific and medical needs in a commercial setting to be able to impact patients.
Mike has served as a member of NIH study sections for in vivo molecular imaging centers, designed and led global clinical trials for the registration of digital pathology devices and served as a board member and president of the Digital Pathology Association (DPA). Under his leadership, the DPA successfully collaborated with the FDA to establish industry wide regulatory guidance and clinical trial designs for the clinical use of digital pathology devices. He currently serves on the DPA executive committee as immediate past-president, and on the DPA Foundation’s board of directors. Dr. Montalto earned his PhD in tumor biology from Albany Medical College and received his post-doctoral training in anti-inflammatory drug discovery and whole animal physiology at Brigham and Women’s Hospital, Harvard Medical School.